Bioreactor technology advances can offer seamless manufacturing scale-up.

Cell Culture Scale-up Challenges

PAT advances are enabling improved process understanding and control.

Control Strategies for Perfusion Cell Culture

Cell-culture optimization may see benefits such as product titer and quality.

Synthetic Biology-Based Approach to Cell Culture

Feliza Mirasol is the science editor for 

Articles

Cell-culture optimization may see benefits from a synthetic biology-based approach that improves product titer, quality, and time.

Cultivating a Synthetic Biology-Based Approach to Improving Cell Culture

Establishing an automated inline dilution system can potentially ease bottlenecking delays resulting from higher upstream yields.

Using Automated Inline Dilution to Ease Bottlenecking

Cynthia A. Challener, PhD, is a contributing editor to BioPharm International.

PAT advances are enabling improved process understanding, process control, and error prevention.

An innovation such as synthetic biology can develop a consistently stable starting cell line for cell therapy source material.

Synthetic Biology Offers a Solution to Cell Therapy Source Material Constraints

Melisa Carpio is a global technology consultant for Cell Culture Technologies at Sartorius North America.

Bioreactor technology advances can offer seamless manufacturing scale-up and can reduce the timeline and cost of biologics production.

Current Challenges with Cell Culture Scale-up for Biologics Production 

This article will explore the traditional path from the laboratory to the clinic and how the fixed-bed technology provides an alternative solution to meet commercial demands.

Commercial Production of Gene Therapies Using Suspension or Adherent Cell Lines 

Process modeling offers an opportunity to troubleshoot for and anticipate difficult aspects of a bioprocess.

Using Process Modeling to Troubleshoot a Bioprocess

Innovative approaches, including ready-to-use materials and in-line dilution, can significantly streamline overall bioprocessing operations.

Improving mAb Manufacturing Productivity by Optimizing Buffer and Media Prep Process Flow

Therapies for early and late treatment and passive immunization of COVID-19 are needed and can be developed using antibodies from recovered patients.

Plasma-Based Antibody Therapies Battle Against COVID-19

Synthetic biology has advanced the scope and scale with which biologically derived therapeutics can be developed.

Upstream Processing

Cell Culture Scale-up Challenges

Control Strategies for Perfusion Cell Culture

Synthetic Biology-Based Approach to Cell Culture